Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 166-181 http://medscipublisher.com/index.php/cge 174 NGS has been instrumental in advancing the application of liquid biopsies in breast cancer. By sequencing ctDNA, researchers can detect genetic mutations and alterations associated with breast cancer, even at low frequencies. This enables early detection of cancer, monitoring of minimal residual disease, and identification of emerging resistance mutations during treatment (Chen and Zhao, 2019; Esagian et al., 2020). For instance, a study demonstrated that NGS-based liquid biopsy could identify clinically relevant mutations in advanced non-small cell lung cancer, highlighting its potential applicability in breast cancer as well (Esagian et al., 2020). Despite its promise, the implementation of liquid biopsies in clinical practice faces several challenges. One of the primary issues is the sensitivity and specificity of ctDNA detection, particularly in early-stage cancers where the ctDNA levels are low. Additionally, standardizing the methodologies and ensuring the reproducibility of results across different platforms and laboratories is crucial for the widespread adoption of liquid biopsies in clinical settings. In conclusion, genomic technologies such as NGS, CRISPR-Cas9, and liquid biopsies are transforming breast cancer research. These technologies are providing deeper insights into the genetic landscape of breast cancer, identifying novel mutations, and enabling personalized treatment approaches. However, addressing the associated challenges is essential to fully realize their potential in improving breast cancer diagnosis, treatment, and patient outcomes. 7 Genetic Testing and Personalized Medicine in Breast Cancer 7.1 Genetic counseling and testing guidelines Genetic counseling and testing have become integral components of breast cancer management, particularly for individuals with a family history of the disease or known genetic predispositions. Current practices emphasize the importance of genetic counseling both before and after testing to ensure patients understand the implications of their results. For instance, the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) have developed guidelines to assist healthcare providers in making informed decisions about genetic testing and counseling (Hampel et al., 2015). These guidelines recommend genetic counseling at multiple points in the care pathway, although the format and timing can vary across different regions and institutions (Forbes et al., 2019). Despite these recommendations, there are significant challenges in the implementation of genetic testing. One major issue is the underutilization of genetic counseling services. Studies have shown that a substantial proportion of eligible patients are not referred for genetic counseling, which can lead to missed opportunities for early intervention and personalized treatment (Heller et al., 2021; Mendenhall et al., 2024). Additionally, there is a shortage of trained genetic counselors, which is expected to worsen as the demand for genetic testing increases (Singer et al., 2019). This shortage can compromise the quality of care and delay the integration of genetic information into clinical practice. 7.2 Personalized treatment approaches The role of genetic information in guiding targeted therapies for breast cancer is increasingly recognized. Advances in cancer genetics and genomics have enabled the identification of specific mutations that can be targeted with precision therapies. For example, BRCA1 and BRCA2 mutations are well-known markers that can influence treatment decisions, including the use of poly(ADP-ribose) polymerase (PARP) inhibitors (Dancey et al., 2012; Forbes et al., 2019). These targeted therapies have shown promise in improving outcomes for patients with specific genetic profiles. Moreover, the integration of genetic testing into clinical practice allows for more personalized treatment plans. Genetic information can guide decisions regarding the use of chemotherapy, radiotherapy, and surgical interventions. For instance, patients with certain genetic mutations may benefit from more aggressive treatment strategies or prophylactic surgeries to reduce the risk of cancer recurrence (Mendenhall et al., 2024). The use of multigene panel testing has further expanded the scope of genetic information available, enabling the identification of additional mutations that may influence treatment decisions (Heller et al., 2021).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==